Dendreon Corp.
3005 First Avenue
Seattle,
WA 98121
United States - Map
Phone: 206-256-4545
Fax: 206-256-0571
Web Site: http://www.dendreon.com
| Dendreon Corporation, a biotechnology company, engages in the discovery, development, and commercialization of therapeutics to enhance cancer treatment options for patients. The companys product portfolio includes active cellular immunotherapy, monoclonal antibody, and small molecule product candidates to treat various cancers. Its product candidates comprise Provenge (sipuleucel-T), an active cellular immunotherapy that has completed two Phase III trials for the treatment of asymptomatic, metastatic, and androgen-independent prostate cancer; and Neuvenge (lapuleucel-T), an investigational active immunotherapy for the treatment of patients with breast, ovarian, and other solid tumors expressing HER2/neu. The company also has a range of products in preclinical studies, which include CEA for the treatment of breast, lung, and colon cancer; CA-9 (MN) for the treatment of kidney, colon, and cervical cancer; Anti-Serine Protease for the treatment of multiple cancers; and Anti-HLA-DR for the treatment of hematologic malignancies, as well as TRPM8 for the treatment of lung, breast, prostate, and colon cancer. Dendreon Corporation, formerly known as Activated Cell Therapy, Inc., was founded in 1992 and is headquartered in Seattle, Washington. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. Mitchell H. Gold M.D., 41
Chief Exec. Officer, Pres |
$
712.00K |
$
0 | Mr. Gregory T. Schiffman MBA, CPA, 50
Chief Financial Officer, Sr. VP and Treasurer |
$
482.00K |
$
0 | Dr. David L. Urdal Ph.D., 59
Chief Scientific Officer, Sr. VP |
$
517.00K |
$
0 | Dr. Mark Frohlich M.D., 47
Chief Medical Officer and Sr. VP of Clinical Affairs |
$
396.00K |
$
0 | Mr. Richard F. Hamm Jr., 49
Sr. VP of Corp. Devel., Gen. Counsel and Sec. |
$
441.00K |
$
0 |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
1.48% Nasdaq 
Profile
